Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer

M. Kusama, K. Miyauchi, H. Aoyama, M. Sano, M. Kimura, S. Mitsuyama, K. Komaki, Hiroyoshi Doihara

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a multicenter randomized comparative study between April 1997 and March 2001. As adjuvant therapy, 20 mg of TAM or 40 mg of TOR was administered for 1 year. The levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-1 (Apo A-1), apolipoprotein A(Apo B), and lipoprotein a (Lp(a)) were measured prior to administration and 3, 6, and 12 months after the start of administration. TC, LDL-C, Lp(a) and Apo B significantly decreased from the third month of administration compared with values before the start of administration in both the TOR and TAM groups. HDL-C significantly increased from the third month only in the TOR group. TG significantly increased in the TAM group but significantly decreased in the TOR group in the 12th month of administration. When these two groups were compared, HDL-C was significantly higher ( p <0.01) and TG was significantly lower ( p <0.01) in the TOR group in the 12th month. Improvement of abnormal values of TG, HDL-C and LDL-C was better in the TOR group than in the TAM group after administration for 12 months. The effect on lipid metabolism showed different profiles between the two selective estrogen receptor modulators (SERMs), and TOR gave better results than TAM.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalBreast Cancer Research and Treatment
Volume88
Issue number1
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Toremifene
Tamoxifen
Breast Neoplasms
Lipids
Serum
HDL Cholesterol
Triglycerides
LDL Cholesterol
Apolipoproteins B
Cholesterol
Apolipoproteins A
Selective Estrogen Receptor Modulators
Lipoprotein(a)
Apolipoprotein A-I
Lipid Metabolism
Lymph Nodes
Hormones
Neoplasm Metastasis

Keywords

  • adjuvant therapy
  • high-density lipoprotein cholesterol
  • low-density lipoprotein cholesterol
  • postmenopausal breast cancer
  • SERMs
  • serum lipid
  • tamoxifen
  • toremifene
  • total cholesterol
  • triglyceride

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. / Kusama, M.; Miyauchi, K.; Aoyama, H.; Sano, M.; Kimura, M.; Mitsuyama, S.; Komaki, K.; Doihara, Hiroyoshi.

In: Breast Cancer Research and Treatment, Vol. 88, No. 1, 11.2004, p. 1-8.

Research output: Contribution to journalArticle

Kusama, M. ; Miyauchi, K. ; Aoyama, H. ; Sano, M. ; Kimura, M. ; Mitsuyama, S. ; Komaki, K. ; Doihara, Hiroyoshi. / Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. In: Breast Cancer Research and Treatment. 2004 ; Vol. 88, No. 1. pp. 1-8.
@article{7683f9cf98944b609e38c3bd324b0439,
title = "Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer",
abstract = "This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a multicenter randomized comparative study between April 1997 and March 2001. As adjuvant therapy, 20 mg of TAM or 40 mg of TOR was administered for 1 year. The levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-1 (Apo A-1), apolipoprotein A(Apo B), and lipoprotein a (Lp(a)) were measured prior to administration and 3, 6, and 12 months after the start of administration. TC, LDL-C, Lp(a) and Apo B significantly decreased from the third month of administration compared with values before the start of administration in both the TOR and TAM groups. HDL-C significantly increased from the third month only in the TOR group. TG significantly increased in the TAM group but significantly decreased in the TOR group in the 12th month of administration. When these two groups were compared, HDL-C was significantly higher ( p <0.01) and TG was significantly lower ( p <0.01) in the TOR group in the 12th month. Improvement of abnormal values of TG, HDL-C and LDL-C was better in the TOR group than in the TAM group after administration for 12 months. The effect on lipid metabolism showed different profiles between the two selective estrogen receptor modulators (SERMs), and TOR gave better results than TAM.",
keywords = "adjuvant therapy, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, postmenopausal breast cancer, SERMs, serum lipid, tamoxifen, toremifene, total cholesterol, triglyceride",
author = "M. Kusama and K. Miyauchi and H. Aoyama and M. Sano and M. Kimura and S. Mitsuyama and K. Komaki and Hiroyoshi Doihara",
year = "2004",
month = "11",
doi = "10.1007/s10549-004-4384-z",
language = "English",
volume = "88",
pages = "1--8",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer

AU - Kusama, M.

AU - Miyauchi, K.

AU - Aoyama, H.

AU - Sano, M.

AU - Kimura, M.

AU - Mitsuyama, S.

AU - Komaki, K.

AU - Doihara, Hiroyoshi

PY - 2004/11

Y1 - 2004/11

N2 - This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a multicenter randomized comparative study between April 1997 and March 2001. As adjuvant therapy, 20 mg of TAM or 40 mg of TOR was administered for 1 year. The levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-1 (Apo A-1), apolipoprotein A(Apo B), and lipoprotein a (Lp(a)) were measured prior to administration and 3, 6, and 12 months after the start of administration. TC, LDL-C, Lp(a) and Apo B significantly decreased from the third month of administration compared with values before the start of administration in both the TOR and TAM groups. HDL-C significantly increased from the third month only in the TOR group. TG significantly increased in the TAM group but significantly decreased in the TOR group in the 12th month of administration. When these two groups were compared, HDL-C was significantly higher ( p <0.01) and TG was significantly lower ( p <0.01) in the TOR group in the 12th month. Improvement of abnormal values of TG, HDL-C and LDL-C was better in the TOR group than in the TAM group after administration for 12 months. The effect on lipid metabolism showed different profiles between the two selective estrogen receptor modulators (SERMs), and TOR gave better results than TAM.

AB - This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a multicenter randomized comparative study between April 1997 and March 2001. As adjuvant therapy, 20 mg of TAM or 40 mg of TOR was administered for 1 year. The levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-1 (Apo A-1), apolipoprotein A(Apo B), and lipoprotein a (Lp(a)) were measured prior to administration and 3, 6, and 12 months after the start of administration. TC, LDL-C, Lp(a) and Apo B significantly decreased from the third month of administration compared with values before the start of administration in both the TOR and TAM groups. HDL-C significantly increased from the third month only in the TOR group. TG significantly increased in the TAM group but significantly decreased in the TOR group in the 12th month of administration. When these two groups were compared, HDL-C was significantly higher ( p <0.01) and TG was significantly lower ( p <0.01) in the TOR group in the 12th month. Improvement of abnormal values of TG, HDL-C and LDL-C was better in the TOR group than in the TAM group after administration for 12 months. The effect on lipid metabolism showed different profiles between the two selective estrogen receptor modulators (SERMs), and TOR gave better results than TAM.

KW - adjuvant therapy

KW - high-density lipoprotein cholesterol

KW - low-density lipoprotein cholesterol

KW - postmenopausal breast cancer

KW - SERMs

KW - serum lipid

KW - tamoxifen

KW - toremifene

KW - total cholesterol

KW - triglyceride

UR - http://www.scopus.com/inward/record.url?scp=8744245366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8744245366&partnerID=8YFLogxK

U2 - 10.1007/s10549-004-4384-z

DO - 10.1007/s10549-004-4384-z

M3 - Article

C2 - 15538040

AN - SCOPUS:8744245366

VL - 88

SP - 1

EP - 8

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -